• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Oncology

Imatinib and binimetinib combination is a potential effective treatment for advanced gastrointestinal stromal tumours

byKassandra McFarlaneandSze Wah Samuel Chan
January 24, 2022
in Gastroenterology, Oncology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Combination-treatment resulted in a best ORR of 69.0% and median PFS of 29.9 months

2. MEK inhibition toxicities included rare incidences of left ventricular ejection fraction decrease or dropped head syndrome

Evidence Rating Level: 2 (Good)

Study Rundown: Gastrointestinal stromal tumours (GISTs) often become resistant to imatinib. This study explored the effect of combination imatinib (KIT and PDGFRα inhibitor) with binimetinib (MEK inhibitor targeting ETV1) on overall response rate (ORR), progression-free survival (PFS), overall survival (OS), and toxicity in adult patients with advanced and treatment-naïve GIST. The primary outcome was best ORR, while secondary outcomes included PFS, OS, and toxicity. 50 patients were enrolled in the study, while 43 were evaluable for toxicity and 42 were evaluable for efficacy. By the study cutoff, ORR was confirmed in 29 patients, with the best ORR being 69%. The median PFS at study cutoff was 29.9 months. Median OS was not estimable, but 72.8% of patients were alive at 48 months. The most common adverse events (AEs) were periorbital and peripheral edema, acneiform rash, and diarrhea, among others. No adverse effects were unexpected and there were no severe AEs due to medications in the trial. Limitations to this study include small sample size. Overall, the of combination imatinib and binimetinib therapy for treatment-naïve advanced GIST is effective and warrants further investigation comparing to frontline imatinib.

Click to read the study in The Journal of Clinical Oncology

Relevant Reading: Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial

RELATED REPORTS

#VisualAbstract: Combination therapy using conformation-specific KIT inhibitors associated with clinical benefit in patients with advanced gastrointestinal stromal tumors

In-Depth [randomized controlled trial]: This phase 2, single-centre, single-arm trial enrolled 50 adult patients with treatment-naĂŻve GIST. Patients in the trial received 2 weeks of imatinib-only followed by the combination treatment of imatinib with binimetinib. 42 patients met the eligibility for efficacy assessment and 43 were evaluable for toxicity. The primary outcome was ORR and it was found that the combination-treatment resulted in a best ORR of 69.0% (95% confidence interval (CI), 52.9% to 82.4%). Median PFS at study cutoff was 29.9 months (95% CI, 24.2 months to not estimable). While median OS was not mature, 72.8% (95% CI, 56.9% to 93.1%) of patients were alive at 48 months. Some of the most common adverse events (AEs) included periorbital (69.8%) and peripheral (79.1%) edema, acneiform rash (74.4%), and diarrhea (60.5%). MEK specific inhibition toxicities included left ventricular ejection fraction decrease (2 patients) and dropped head syndrome (3 patients). No adverse effects were unexpected during the trial. 8 patients left the trial because of adverse events associated with treatment

Image: PD

©2022 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: EVT1gistKIT
Previous Post

Metformin may improve survival for advanced lung adenocarcinoma patients with higher BMI and taking EGFR-TKI therapy

Next Post

Oral microbiome therapy reduced Clostridioides difficile recurrence

RelatedReports

#VisualAbstract: Combination therapy using conformation-specific KIT inhibitors associated with clinical benefit in patients with advanced gastrointestinal stromal tumors
StudyGraphics

#VisualAbstract: Combination therapy using conformation-specific KIT inhibitors associated with clinical benefit in patients with advanced gastrointestinal stromal tumors

July 20, 2021
Next Post
[Physician Comment] The extent of C. difficile infections may not differ in light of immune status

Oral microbiome therapy reduced Clostridioides difficile recurrence

Transcatheter aortic valve replacement provides only minor benefit to quality of life

Secondary Antibiotic Prophylaxis Reduces Rheumatic Heart Disease Progression

Early language exposure is predictive of language skills and IQ in school-age children

Endometriosis associated with early natural menopause

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Weighted vests and resistance training confer similar outcomes for bone density in the elderly
  • Breast cancer survivors may have a lower risk of Alzheimer’s dementia
  • Evaluating scar outcomes in pediatric burn patients following skin grafting 
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.